226 related articles for article (PubMed ID: 23937785)
1. The terminally ill, access to investigational drugs, and FDA rules.
Blake V
Virtual Mentor; 2013 Aug; 15(8):687-91. PubMed ID: 23937785
[No Abstract] [Full Text] [Related]
2. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
3. A study in futility: Abigail Alliance for Better Access to Developmental Drugs will not expand access to experimental drugs for the terminally ill.
Ochs A
Seton Hall Law Rev; 2009; 39(2):559-603. PubMed ID: 19462540
[No Abstract] [Full Text] [Related]
4. Access before approval--a right to take experimental drugs?
Okie S
N Engl J Med; 2006 Aug; 355(5):437-40. PubMed ID: 16885545
[No Abstract] [Full Text] [Related]
5. No way to save a life: allowing terminally ill patients access to drugs that have not completed clinical trials is a dangerous move.
Moss RW
New Sci; 2006 Jun 3-9; 190(2554):21. PubMed ID: 16832956
[No Abstract] [Full Text] [Related]
6. Cancer and the constitution--choice at life's end.
Annas GJ
N Engl J Med; 2007 Jul; 357(4):408-13. PubMed ID: 17652658
[No Abstract] [Full Text] [Related]
7. Individual patient treatment use of unapproved drugs: a new option for the seriously ill.
Simon LS; Green A
J Pain Palliat Care Pharmacother; 2010 Mar; 24(1):19-22. PubMed ID: 20345195
[TBL] [Abstract][Full Text] [Related]
8. The proper focus for FDA regulations: why the fundamental right to self-preservation should allow terminally ill patients with no treatment options to attempt to save their lives.
Puckett A
SMU Law Rev; 2007; 60(2):635-65. PubMed ID: 17849632
[No Abstract] [Full Text] [Related]
9. Should terminally ill patients have access to phase I drugs?
Bristol N
Lancet; 2007 Mar; 369(9564):815-6. PubMed ID: 17366691
[No Abstract] [Full Text] [Related]
10. Expanded access to investigational drugs for treatment use. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173
[TBL] [Abstract][Full Text] [Related]
11. Practical, legal, and ethical issues in expanded access to investigational drugs.
Darrow JJ; Sarpatwari A; Avorn J; Kesselheim AS
N Engl J Med; 2015 Jan; 372(3):279-86. PubMed ID: 25587952
[No Abstract] [Full Text] [Related]
12. Charging for investigational drugs under an investigational new drug application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2009 Aug; 74(155):40871-900. PubMed ID: 19691172
[TBL] [Abstract][Full Text] [Related]
13. US proposal to expand access to untested drugs draws fire.
Waltz E
Nat Med; 2007 Feb; 13(2):111. PubMed ID: 17290254
[No Abstract] [Full Text] [Related]
14. Recent developments in health law.
Lee WB; Shachar C; Chang P
J Law Med Ethics; 2008; 36(1):191-9. PubMed ID: 18315772
[No Abstract] [Full Text] [Related]
15. "Right to Try" Laws: The Gap between Experts and Advocates.
Dresser R
Hastings Cent Rep; 2015; 45(3):9-10. PubMed ID: 25944200
[No Abstract] [Full Text] [Related]
16. The strange allure of state "right-to-try" laws.
Zettler PJ; Greely HT
JAMA Intern Med; 2014 Dec; 174(12):1885-6. PubMed ID: 25264589
[No Abstract] [Full Text] [Related]
17. Access for the terminally ill to experimental medical innovations: a three-pronged threat.
Bender S; Flicker L; Rhodes R
Am J Bioeth; 2007 Oct; 7(10):3-6. PubMed ID: 17926208
[No Abstract] [Full Text] [Related]
18. Food and Drug Administration responds to pressure for expanded drug access.
Brower V
J Natl Cancer Inst; 2014 Jun; 106(6):dju171. PubMed ID: 24907387
[No Abstract] [Full Text] [Related]
19. Right to try?
Lieu CH; Sorkin A; Messersmith WA
J Clin Oncol; 2015 May; 33(13):1518. PubMed ID: 25779561
[No Abstract] [Full Text] [Related]
20. Access to investigational drugs in the USA.
Lancet; 2007 Aug; 370(9587):540. PubMed ID: 17707730
[No Abstract] [Full Text] [Related]
[Next] [New Search]
